Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Biochim Biophys Acta ; 1830(3): 2804-12, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23201204

RESUMO

BACKGROUND: The poly-gamma-D-glutamic acid (PGA) capsule, a major virulence factor of Bacillus anthracis, protects bacilli from immune surveillance and allows its unimpeded growth in the host. Recently, the importance of the PGA in the pathogenesis of anthrax infection has been reported. The PGA capsule is associated with lethal toxin (LT) in the blood of experimentally infected animals and enhances the cytotoxicity of LT. METHODS: To investigate the role of anti-PGA Abs on progression of anthrax infection, two mouse anti-PGA mAbs with K(d) values of 0.8 microM and 2.6 microM respectively were produced and in silico three dimensional (3D) models of mAbs with their cognitive PGA antigen complex were analyzed. RESULTS: Anti-PGA mAbs specifically bound encapsulated B. anthracis H9401 and showed opsonophagocytosis activity against the bacteria with complement. The enhancement effect of PGA on LT-mediated cytotoxicity was confirmed ex vivo using mouse bone marrow-derived macrophages and was effectively inhibited by anti-PGA mAb. Passive immunization of mAb completely protected mice from PGA-enhanced LT toxicity and partially rescued mice from anthrax spore challenges. 3D structure models of these mAbs and PGA complex support specific interactions between CDR and cognitive PGA. These results indicate that mouse mAb against PGA capsule prevents the progress of anthrax disease not only by eliminating the vegetative form of encapsulated B. anthracis but also by inhibiting the enhanced cytotoxic activity of LT by PGA through specific binding with PGA capsule antigen. GENERAL SIGNIFICANCE: Our results suggest a potential role for PGA antibodies in preventing and treating anthrax infection.


Assuntos
Vacinas contra Antraz/administração & dosagem , Antraz/prevenção & controle , Anticorpos Antibacterianos/administração & dosagem , Anticorpos Monoclonais/administração & dosagem , Antígenos de Bactérias/imunologia , Cápsulas Bacterianas/imunologia , Imunização Passiva , Ácido Poliglutâmico/análogos & derivados , Animais , Antraz/imunologia , Antraz/microbiologia , Antraz/mortalidade , Anticorpos Antibacterianos/biossíntese , Anticorpos Monoclonais/biossíntese , Bacillus anthracis/efeitos dos fármacos , Bacillus anthracis/imunologia , Bacillus anthracis/patogenicidade , Toxinas Bacterianas/imunologia , Células Cultivadas , Feminino , Humanos , Cinética , Macrófagos/efeitos dos fármacos , Macrófagos/imunologia , Macrófagos/microbiologia , Camundongos , Camundongos Endogâmicos BALB C , Simulação de Acoplamento Molecular , Ácido Poliglutâmico/antagonistas & inibidores , Ácido Poliglutâmico/imunologia , Esporos Bacterianos/efeitos dos fármacos , Esporos Bacterianos/imunologia , Esporos Bacterianos/patogenicidade , Análise de Sobrevida , Fatores de Virulência/antagonistas & inibidores , Fatores de Virulência/imunologia
2.
Curr Opin Pharmacol ; 4(1): 85-90, 2004 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-15018844

RESUMO

Abnormal protein aggregation is a hallmark of many neurodegenerative diseases. However, the mechanism by which protein aggregates induce neurodegneration remains controversial. Recently proposed mechanisms of neuronal death in polyglutamine expansion diseases include activation of caspases and associated cell death pathways, interference with transcriptional regulation, downregulation of survival pathways and obstruction of axonal transport. Because the expression of expanded polyglutamine in selected neuronal populations can adversely affect multiple aspects of neuronal survival and function, we propose that effective therapeutic approaches might have to target the upstream mechanism of neurotoxicity by selectively inhibiting the formation of intraneuronal aggregates and increasing the degradation of mutant proteins.


Assuntos
Morte Celular/efeitos dos fármacos , Doenças Neurodegenerativas/fisiopatologia , Ácido Poliglutâmico/efeitos adversos , Animais , Doenças Neurodegenerativas/genética , Peptídeos/metabolismo , Ácido Poliglutâmico/antagonistas & inibidores , Ácido Poliglutâmico/uso terapêutico
3.
Biochemistry ; 37(23): 8395-404, 1998 Jun 09.
Artigo em Inglês | MEDLINE | ID: mdl-9622491

RESUMO

In this work, we report on a novel enzyme, tubulin polyglutamylase, which catalyzes the posttranslational formation of polyglutamyl side chains onto alpha- and beta-tubulin. The length of the polyglutamyl side chain regulates the interaction between tubulin and various microtubule-associated proteins. We first developed an in vitro glutamylation assay. Activity measured in brain, a tissue particularly enriched with glutamylated tubulin, decreases during postnatal development. Thus, brains from 3-day-old mice were chosen as the starting material, and the enzyme was purified approximately 1000-fold. Its Mr was estimated to be 360K and its sedimentation coefficient 10 s. The enzyme catalyzes the MgATP-dependent addition of l-glutamate onto tubulin subunits. Microtubules are much better substrates than unpolymerized tubulin, and the reaction is very specific for glutamate, other amino acids or glutamate analogues not being substrates. Moreover, glutamyl units are added sequentially onto tubulin, leading to progressive elongation of the polyglutamyl side chains. Side chains of one to six or seven glutamyl units were obtained with microtubules, whereas much longer side chains (up to 15-20 units) were formed with unpolymerized tubulin. Interestingly, such very long polyglutamyl side chains were recently detected in some situations in vivo.


Assuntos
Ácido Poliglutâmico/isolamento & purificação , Ácido Poliglutâmico/metabolismo , Processamento de Proteína Pós-Traducional , Tubulina (Proteína)/isolamento & purificação , Tubulina (Proteína)/metabolismo , Trifosfato de Adenosina/metabolismo , Sequência de Aminoácidos , Animais , Animais Recém-Nascidos , Encéfalo/enzimologia , Estabilidade Enzimática , Ácido Glutâmico/metabolismo , Células HeLa , Humanos , Concentração de Íons de Hidrogênio , Camundongos , Dados de Sequência Molecular , Peptídeo Sintases , Ácido Poliglutâmico/antagonistas & inibidores , Ácido Poliglutâmico/química , Cloreto de Potássio/farmacologia , Cloreto de Sódio/farmacologia , Solubilidade , Especificidade por Substrato , Tubulina (Proteína)/química , Moduladores de Tubulina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA